Sarepta Therapeutics Inc. (SRPT) Plunges 5.92% Amid Fatality Concerns

Sarepta Therapeutics Inc. (SRPT) shares plunged 5.92% today, marking the fourth consecutive day of decline, with a total drop of 21.08% over the past four days. The stock price hit its lowest level since November 2017, with an intraday decline of 6.60%.

Sarepta's stock has been under significant pressure due to recent developments in its Elevidys gene therapy program. The company announced a fatality involving a 16-year-old US patient who died of acute liver failure in March 2025. This incident led to a notable decline in Sarepta's stock price, reflecting investor concerns over the safety of the program.

Despite the fatality, the independent data monitoring committee (IDMC) reviewed the benefit-risk profile of Sarepta's Elevidys trials and determined that it remains favorable. This assessment indicates ongoing confidence in the program's potential, although the incident has raised concerns among investors and analysts.

Analysts have responded to these developments with mixed sentiments. Scotiabank analyst Louise Chen maintained a Hold rating for Sarepta, with a price target set at $80.00. Meanwhile, Deutsche Bank Aktiengesellschaft lowered its price target for Sarepta's shares, reflecting cautious investor sentiment and the potential impact of the fatality on the company's future prospects.

These factors combine to create a complex scenario for Sarepta, with significant scrutiny following clinical trial developments and varying analyst perspectives affecting investor confidence. The company will need to navigate these challenges carefully to regain investor trust and stabilize its stock price.